Gao X P, Yuan J, Mei X H, Feng Z J, Guo X, Ji G, Song Y Y, Wei J P
Department of Gastrointestinal Surgery, The Affiliated Yuncheng Central Hospital of Shanxi Medical University, Yuncheng 044000, China.
Department of Gastrointestinal Surgery, The Affiliated Yuncheng Central Hospital of Shanxi Medical University, Yuncheng 044000, China Changzhi Medical College, Changzhi 046000, China.
Zhonghua Wei Chang Wai Ke Za Zhi. 2025 Jul 25;28(7):758-766. doi: 10.3760/cma.j.cn441530-20241029-00356.
To evaluate the short-term safety and efficacy of total laparoscopic, laparoscopy-assisted, and open total gastrectomy in patients with gastric cancer who have undergone neoadjuvant therapy. In this retrospective cohort study, relevant clinical data on 243 patients who had undergone radical total gastrectomy after receiving neoadjuvant therapy were collected. These patients had been admitted to the First Affiliated Hospital of Air Force Medical University, Yuncheng Central Hospital of Shanxi Province, and Heji Hospital Affiliated to Changzhi Medical College between January 2020 and April 2024. Among them, 202 were male (83.1%) and 41 were female (16.9%), and their average age was 61.3±8.1 years. The patients were allocated to three groups according to surgical procedure: total laparoscopic (68 cases), laparoscopic- assisted (79 cases), and open surgery (96 cases). We compared relevant baseline characteristics, neoadjuvant treatment, intraoperative and postoperative conditions, postoperative histopathological findings, and related complications between these three groups. There were no statistically significant differences in baseline characteristics or neoadjuvant treatment between the three groups (all >0.05). The operative time was longer in the total laparoscopic group than in the laparoscopic-assisted and open surgery groups (267.7±37.9 minutes vs. 243.9±38.3 minutes vs. 219.7±41.2 minutes, respectively; =7,112.278; <0.001). However, more lymph nodes were harvested in the total laparoscopic group than in the laparoscopic-assisted and open surgery groups (27.8±4.8 vs. 27.4±6.3 vs. 27.2±5.1, respectively; =6.042;=0.002). Additionally, the total laparoscopic group had shorter times to first postoperative flatus (2.3±0.7 days vs. 2.4±0.7 days vs. 2.6±0.6 days, respectively; =5.094;=0.006] and first postoperative bowel movement (2.9±0.5 days vs. 3.0±0.6 days vs. 3.0±0.6 days, respectively; =3.929;=0.020). There were no statistically significant differences in intraoperative blood loss, intraoperative transfusion rates, postoperative intensive care unit admission rates, maximum tumor diameter, number of positive lymph nodes dissected, TNM stage, time to first postoperative oral intake, time to drain removal, or length of hospital stay between the three groups (all >0.05). Among the 243 patients, 22 developed postoperative complications, making the overall complication rate 9.1%. Six patients (8.8%) in the total laparoscopic group developed complications, comprising two (2.9%) Grade IIIa Clavien-Dindo complications. One of these patients (1.5%) was readmitted within 30 days due to complications. Seven patients (8.9%) in the laparoscopic-assisted group developed complications, comprising two (2.5%) Grade IIIa Clavien-Dindo complications. One of these patients was readmitted within 30 days and another was within 90 days due to complications. Nine patients (9.4%) in the open surgery group developed complications, comprising four (4.2%) Grade IIIa Clavien-Dindo complications. Two patients (2.1%) were readmitted within 30 days and another (1.0%) within 90 days due to complications. There were no statistically significant differences among the three surgical approaches in overall postoperative complication rates, Clavien-Dindo grades, or readmission rates 30 and 90 days postoperatively (all >0.05). In patients with gastric cancer who have undergone neoadjuvant therapy, there are no significant differences in the overall safety and short-term effectiveness of the three surgical procedures. Although the operative time is longer for total laparoscopic total gastrectomy, this procedure offers the advantages of faster postoperative recovery and earlier resumption of feeding.
评估新辅助治疗后胃癌患者行全腹腔镜、腹腔镜辅助及开放全胃切除术的短期安全性和疗效。在这项回顾性队列研究中,收集了243例接受新辅助治疗后行根治性全胃切除术患者的相关临床资料。这些患者于2020年1月至2024年4月期间入住空军军医大学第一附属医院、山西省运城市中心医院和长治医学院附属和济医院。其中,男性202例(83.1%),女性41例(16.9%),平均年龄为61.3±8.1岁。根据手术方式将患者分为三组:全腹腔镜组(68例)、腹腔镜辅助组(79例)和开放手术组(96例)。我们比较了这三组患者的相关基线特征、新辅助治疗情况、术中及术后情况、术后组织病理学结果和相关并发症。三组患者的基线特征或新辅助治疗情况差异均无统计学意义(均>0.05)。全腹腔镜组的手术时间长于腹腔镜辅助组和开放手术组(分别为267.7±37.9分钟、243.9±38.3分钟和219.7±41.2分钟;=7112.278;<0.001)。然而,全腹腔镜组切除的淋巴结多于腹腔镜辅助组和开放手术组(分别为27.8±4.8枚、27.4±6.3枚和27.2±5.1枚;=6.042;=0.002)。此外,全腹腔镜组术后首次排气时间(分别为2.3±0.7天、2.4±0.7天和2.6±0.6天;=5.094;=0.006)和首次排便时间(分别为2.9±0.5天、3.0±0.6天和3.0±0.6天;=3.929;=0.020)更短。三组患者在术中出血量、术中输血率、术后重症监护病房入住率、最大肿瘤直径、清扫阳性淋巴结数量、TNM分期、术后首次经口进食时间、引流管拔除时间或住院时间方面差异均无统计学意义(均>0.05)。243例患者中,22例发生术后并发症,总体并发症发生率为9.1%。全腹腔镜组6例患者(8.8%)发生并发症,其中2例(2.9%)为Clavien-DindoⅢa级并发症。其中1例患者(1.5%)因并发症在30天内再次入院。腹腔镜辅助组7例患者(8.9%)发生并发症,其中2例(2.5%)为Clavien-DindoⅢa级并发症。其中1例患者因并发症在30天内再次入院,另1例在90天内再次入院。开放手术组9例患者(9.4%)发生并发症,其中4例(4.2%)为Clavien-DindoⅢa级并发症。2例患者(2.1%)因并发症在30天内再次入院,另1例(1.0%)在90天内再次入院。三种手术方式在总体术后并发症发生率、Clavien-Dindo分级或术后30天和90天的再入院率方面差异均无统计学意义(均>0.05)。对于接受新辅助治疗的胃癌患者,三种手术方式的总体安全性和短期有效性无显著差异。虽然全腹腔镜全胃切除术的手术时间较长,但该手术具有术后恢复快、进食恢复早的优点。